‘The biotech giant that developed the first effective coronavirus treatment is now looking to expand its impact. Gilead Sciences CEO Daniel O'Day said Monday that the company would start testing an inhaled version of the antiviral drug remdesivir in August. Currently, the drug is given as an intravenous infusion. If remdesivir is effective when given through a nebulizer, that "could have significant implications in helping to stem the tide of the pandemic," O'Day wrote in an open letter.’
Read here (Business Insider, June 22, 2020)
Worst ever Covid variant? Omicron
John Campbell shares his findings on Omicron. View here (Youtube, Nov 27, 2021)
-
‘Infectious diseases experts have questioned the need for continued widespread enforcement of TraceTogether and SafeEntry rules as Singapore...
-
‘Much was riding on the Oxford vaccine, a British-led endeavour also involving UK drugs firm AstraZeneca. Prime Minister Boris Johnson’s gov...
-
‘It appears that vaccine hesitancy is due to lack of information and trust. Despite the government's assurances about Covid-19 vaccines,...